PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30783430-0	2019	Ropivacaine at different concentrations on intrapartum fever, IL-6 and TNF-alpha in parturient with epidural labor analgesia.	Ropivacaine	0-11	tumor necrosis factor	Homo sapiens	71-80	
35428182-12	2022	Furthermore, ropivacaine contributed to the release of pro-inflammatory cytokines (IL-6 and TNF-alpha) and inhibited the secretion of anti-inflammatory cytokines of keratinocytes (IL-10).	Ropivacaine	13-24	tumor necrosis factor	Homo sapiens	92-101	
31642986-9	2019	RESULTS: The clinically usage concentration of ropivacaine (10-6 M) produced a significant decrease in CD62E expression compared with that produced by TNFalpha only (p < 0.001).	Ropivacaine	47-58	tumor necrosis factor	Homo sapiens	151-159	
9336308-8	1997	Moreover, ropivacaine inhibited the tumor necrosis factor alpha-induced up-regulation of CD11b/CD18 and L-selectin shedding by human leukocytes in vitro.	Ropivacaine	10-21	tumor necrosis factor	Homo sapiens	36-63	
24525631-6	2014	RESULTS: Ropivacaine and lidocaine attenuated TNFalpha-induced Src activation (half-maximal inhibitory concentration [IC50] = 8.611 x 10 M for ropivacaine; IC50 = 5.864 x 10 M for lidocaine) and endothelial nitric oxide synthase phosphorylation (IC50 = 7.572 x 10 M for ropivacaine; IC50 = 6.377 x 10 M for lidocaine).	Ropivacaine	9-20	tumor necrosis factor	Homo sapiens	46-54	
30881912-8	2019	Results: T-correlation analysis showed that in both ropivacaine and bupivacaine groups, the TNF-alpha, IL-6, and IL-1 levels decreased after the block.	Ropivacaine	52-63	tumor necrosis factor	Homo sapiens	92-101	
26475807-0	2015	Clinically relevant concentrations of lidocaine and ropivacaine inhibit TNFalpha-induced invasion of lung adenocarcinoma cells in vitro by blocking the activation of Akt and focal adhesion kinase.	Ropivacaine	52-63	tumor necrosis factor	Homo sapiens	72-80	
26475807-7	2015	RESULTS: Ropivacaine (1 nM-100 muM) and lidocaine (1-100 microM) significantly reduced TNFalpha-induced activation/phosphorylation of Akt, FAK and caveolin-1 in NCI-H838 cells.	Ropivacaine	9-20	tumor necrosis factor	Homo sapiens	87-95	
27631634-0	2016	Ropivacaine, Interleukin-6 and Tumor Necrosis Factor Alpha Plasma Levels during Intermittent Epidural and Continuous Wound Infusion of Ropivacaine for Analgesia after Hysterectomy or Myomectomy: An Observational Study.	Ropivacaine	135-146	tumor necrosis factor	Homo sapiens	31-58	
26475807-8	2015	MMP-9 secretion triggered by TNFalpha was significantly attenuated by both lidocaine and ropivacaine (half-maximal inhibitory concentration [IC50]=3.29x10(-6) M for lidocaine; IC50=1.52x10(-10) M for ropivacaine).	Ropivacaine	89-100	tumor necrosis factor	Homo sapiens	29-37	
26475807-8	2015	MMP-9 secretion triggered by TNFalpha was significantly attenuated by both lidocaine and ropivacaine (half-maximal inhibitory concentration [IC50]=3.29x10(-6) M for lidocaine; IC50=1.52x10(-10) M for ropivacaine).	Ropivacaine	200-211	tumor necrosis factor	Homo sapiens	29-37	
26475807-9	2015	The TNFalpha-induced increase in invasion was completely blocked by both lidocaine (10 microM) and ropivacaine (1 microM).	Ropivacaine	99-110	tumor necrosis factor	Homo sapiens	4-12	
26539251-10	2015	The reversibility of these effects after withdrawal of the anesthetics was attenuated for TNF-alpha/IFN-gamma-stimulated MSCs exposed to ropivacaine and bupivacaine.	Ropivacaine	137-148	tumor necrosis factor	Homo sapiens	90-99	
24525631-6	2014	RESULTS: Ropivacaine and lidocaine attenuated TNFalpha-induced Src activation (half-maximal inhibitory concentration [IC50] = 8.611 x 10 M for ropivacaine; IC50 = 5.864 x 10 M for lidocaine) and endothelial nitric oxide synthase phosphorylation (IC50 = 7.572 x 10 M for ropivacaine; IC50 = 6.377 x 10 M for lidocaine).	Ropivacaine	143-154	tumor necrosis factor	Homo sapiens	46-54	
24525631-6	2014	RESULTS: Ropivacaine and lidocaine attenuated TNFalpha-induced Src activation (half-maximal inhibitory concentration [IC50] = 8.611 x 10 M for ropivacaine; IC50 = 5.864 x 10 M for lidocaine) and endothelial nitric oxide synthase phosphorylation (IC50 = 7.572 x 10 M for ropivacaine; IC50 = 6.377 x 10 M for lidocaine).	Ropivacaine	270-281	tumor necrosis factor	Homo sapiens	46-54	
24525631-9	2014	CONCLUSIONS: Ropivacaine and lidocaine effectively blocked inflammatory TNFalpha signaling in endothelial cells by attenuating p85 recruitment to TNF-receptor-1.	Ropivacaine	13-24	tumor necrosis factor	Homo sapiens	72-80	
22846676-7	2012	RESULTS: Ropivacaine treatment (100 muM) of H838 cells for 20 min decreased basal Src activity by 62% (P=0.003), and both ropivacaine and lidocaine coadministered with tumor necrosis factor-alpha statistically significantly decreased Src-activation and intercellular adhesion molecule-1 phosphorylation, whereas chloroprocaine had no such effect.	Ropivacaine	9-20	tumor necrosis factor	Homo sapiens	168-195	
22846676-11	2012	The observed inhibition of NCI-H838 cell migration by lidocaine and ropivacaine was associated with the inhibition of tumor necrosis factor-alpha-induced Src-activation and intercellular adhesion molecule-1 phosphorylation, providing the first evidence of a molecular mechanism that appears to be independent of their known role as sodium-channel blockers.	Ropivacaine	68-79	tumor necrosis factor	Homo sapiens	118-145